31 poker game
Stock market today: Wall Street slips to a rare back-to-back lossDOJ watchdog review sparks change to policy on lawmaker records
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) SOURCE AmgenShares of Google parent Alphabet rose about 5% on Tuesday after it unveiled a new generation chip that the company said helped overcome a key challenge in quantum computing. Google on Monday introduced a new chip called Willow, which solved in five minutes a computing problem that would take a classical computer more time than the history of the universe. Tech companies are chasing quantum computing in hopes of developing systems that perform at speeds far faster than traditional silicon-based computers. The building blocks of quantum computers, called "qubits", while being fast, are error-prone, making it hard to ensure quantum computers are reliable and commercially viable. The more qubits used in quantum computing, the more errors typically occur. But Google said on Monday it found a way to string together qubits in the Willow chip so that error rates decline as the number of qubits rise, adding that it can also correct errors in real time. Artificial Intelligence(AI) AI for Everyone: Understanding and Applying the Basics on Artificial Intelligence By - Ritesh Vajariya, Generative AI Expert View Program Web Development Java 21 Essentials for Beginners: Build Strong Programming Foundations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development JavaScript Essentials: Unlock AI-Driven Insights with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Collaborative AI Foundations: Working Smarter with Machines By - Prince Patni, Software Developer (BI, Data Science) View Program Web Development Master RESTful APIs with Python and Django REST Framework: Web API Development By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Neil Patel By - Neil Patel, Co-Founder and Author at Neil Patel Digital Digital Marketing Guru View Program Web Development Intermediate C++ Skills: Master Pointers, Structures and File Stream By - Metla Sudha Sekhar, IT Specialist and Developer View Program Entrepreneurship Building Your Winning Startup Team: Key Strategies for Success By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Artificial Intelligence(AI) ChatGPT Mastery from Zero to Hero: The Complete AI Course By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Web Development 12-Factor App Methodology: Principles and Guidelines By - Prince Patni, Software Developer (BI, Data Science) View Program Web Development Maximizing Developer Productivity: The Pomodoro Technique in Practice By - Prince Patni, Software Developer (BI, Data Science) View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program "While (there are) no current uses, (Willow) will have major implications in science, medicine and finance. Willow reduces errors exponentially and could lead to major breakthroughs and discoveries across industries," said Thomas Hayes, chairman and managing member at Great Hill Capital. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories Alphabet's shares were on track for their best day since late April. The stock has risen 25% so far this year, as of Monday's close. The company's shares trade at a 12-month forward price-to-earnings ratio of 19.58, compared with Microsoft's 32.03 and Amazon's 36.79, according to data compiled by LSEG. Earlier this year, Microsoft and quantum computing firm Quantinuum said they achieved a key step in making quantum computers a commercial reality by making them more reliable.How to protect your communications through encryption
Stock market today: Wall Street drifts lower after weak signals on the economyThe Peach Bowl-bound Arizona State Sun Devils have fans around the country hungry for tickets to the New Year's Day game in Georgia. Arizona State is heading to the Peach Bowl on Jan. 1 after winning the Big 12 Championship on Dec. 7. The former President of the Arizona State Alumni Association says his phone is blowing up with ticket requests. The President of the ASU Alumni Association chapter in Georgia is excited to host the event. TEMPE, Ariz. - Arizona State earned the title of Big 12 Champions after defeating the Iowa State Cyclones on Saturday. ASU's next stop? The Peach Bowl in Atlanta where they'll faceoff against either Clemson or Texas. "This year was unbelievable. It really was. It exceeded expectations," said Seth Deitchman a former President of the ASU Alumni Association. Aimee Rene, president of the ASU Alumni Association in Georgia, shared the same sentiment. "Coach Kenny, we're so proud of you and the guys. It's going to be an awesome game. We can't wait," she said. "To be in the Big 12 championship was unbelievable. And then to win it and we were there," said Deitchman. "My son and I were there for the game and it was so great." Rene was also at the Big 12 Championship game in Arlington. "We had gone to Arlington last week and then came back and we got the news the next day that they're going to be right in my backyard. I mean, I cried so many times during like the last few games because I just can't believe it. It's like, so exciting," said Rene. Featured Newcomer Arizona State beats Iowa State in Big 12 title game to earn spot in College Football Playoff The Arizona State Sun Devils beat the Iowa State Cyclones to win the Big 12 Championship in their first year in the conference. They are heading to the first ever College Football Playoff. The Georgia ASU alumni chapter is beyond thrilled to host. "I've already had a ton of people reaching out to us, asking us if they can be involved or if they can, you know, help with the tailgates or, you know, organizations that are inviting us to come out to events. So, there's definitely going to be a lot of a lot of excitement. But also, we are ready to do whatever we need to do to make it a really successful time," said Rene. Flights to Atlanta from Phoenix have already skyrocketed and you can bet tickets for the game will be the same, which is why the former Deitchman says his phone is blowing up. The Peach Bowl is scheduled for New Year's Day at 11:00 a.m. Information for this story was gathered by FOX 10 reporter Lindsey Ragas.
L.A. City Council approves 'mansion tax' spending plan and program guidelinesReport: Institutional neutrality favored at Carolina, Wake, Duke
Donald Trump is returning to the world stage. So is his trollingGERMANTOWN, Tenn. , Dec. 10, 2024 /PRNewswire/ -- Mid-America Apartment Communities, Inc., or MAA (NYSE: MAA), today announced that its board of directors approved a quarterly dividend payment of $1.515 per share of common stock to be paid on January 31, 2025 , to shareholders of record on January 15, 2025 . The increase will raise the annualized dividend payment 3.1% to $6.06 per share of common stock and represents the 15 th consecutive year MAA has increased its dividend to shareholders. As established in prior quarters, the board of directors declared the quarterly common dividend in advance of MAA's earnings announcement that is expected to be made on February 5, 2025 . About MAA MAA is a self-administered real estate investment trust (REIT) and member of the S&P 500. MAA owns or has ownership interest in apartment communities primarily throughout the Southeast, Southwest and Mid-Atlantic regions of the U.S. focused on delivering strong, full-cycle investment performance. For further details, please refer to www.maac.com or contact Investor Relations at investor.relations@maac.com . Certain matters in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended with respect to our expectations for future periods. Such statements include statements made about the payment of common dividends. The ability to meet the payment of common dividends in or contemplated by the forward-looking statements could differ materially from the projection due to a number of factors, including a downturn in general economic conditions or the capital markets, changes in interest rates and other items that are difficult to control such as increases in real estate taxes in many of our markets, as well as the other general risks inherent in the apartment and real estate businesses. Reference is hereby made to the filings of Mid-America Apartment Communities, Inc. with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, reports on Form 8-K, and its annual report on Form 10-K, particularly including the risk factors contained in the latter filing. View original content to download multimedia: https://www.prnewswire.com/news-releases/maa-announces-increase-to-quarterly-common-dividend-302328178.html SOURCE MAA(The Center Square) – U.S. Rep. Andy Biggs, R-Arizona, blasted U.S. Citizenship and Immigration Services Director Ur Jaddou for her agency approving illegal border crossers as sponsors for illegal border crossers. At a U.S. House Judiciary subcommittee hearing , Biggs also pointed out that the sponsors were found to be committing Social Security and other fraud under her watch. Biggs addressed rampant fraud in a program created by Department of Homeland Security Secretary Alejandro Mayorkas for inadmissible citizens of Cuba, Haiti, Nicaragua and Venezuela, who don’t qualify for admission into the U.S. Under Mayorkas, they were flown into the country through a CHNV parole program, used a CBP One phone app to apply for entry, and were released into the country. Part of the process requires having a “supporter” fill out an application on behalf of the CHNV parolee. While Mayorkas claimed app user parolees and supporters were thoroughly vetted, multiple Office of Inspector General reports disproved this claim, expressing security risks at airports. In August, flights of CHNV illegal border crossers were temporarily suspended after a USCIS internal review found that tens of thousands of CHNV fraudulent applications were processed. Supporters used fake Social Security numbers and phone numbers and listed the same physical address on nearly 20,000 applications, according to the report, The Center Square reported . Biggs asked Jaddou if she disputed the fact that supporters used the same Social Security Number on CHNV applications, which “happened at least 3,200 times. The same phone number used at least 3,300 times. The same supporter email address was used on applications nearly 2,000 times.” Jaddou said she didn’t have the report in front of her and didn’t dispute it. “You don’t really want to admit there’s this much rampant fraud,” he said. Biggs next cited examples of fraud that weren’t fixed. “The same exact 184-word response was used on more than 1,800 applications by nearly 194 CHNV supporters,” he said. “More than 460 nonexistent zip codes were used on supported applications on behalf of more than 2,800 CHV aliens. You can dance around and say you don't have the report in front of you, but these are the facts. This program is rife with fraud.” As of Aug. 6, DHS had approved more than 80,000 CHNV supporters for the program who were in the U.S. on a temporary basis. USCIS approved 224 CHNV parolees who were already in the country illegally as sponsors for CHNV parolees that came after them, meaning illegal foreign nationals were sponsoring illegal foreign nationals. USCIS also approved 28,322 illegal foreign nationals shielded from deportation through Temporary Protected Status as CHVN supporters; “19,865 SLEs approved as CHNV supporters, 311 DACA recipients approved as CHNV supporters, 1,300-plus aliens in the U.S. on temporary visas approved as CHNV supporters, 64 refugees approved as CHNV supporters, 19,112 conditional permanent residents approved this season as CHNV supporters,” he said. “That is the program that you are administering. I'm not talking the aliens. I'm not getting into the violation of law of the U.S. code 1182, which states that the use of parole is supposed to be a case-by-case basis.” Biggs said the supporter application process was so rampant with fraud that it was temporarily shut down but wasn’t fixed. The fraud is “still ongoing. We're waiting for the next report to confirm that these things are still going on,” he said. In addition to the USCIS report, a U.S. House Committee on Homeland Security investigation found that "as of mid-October 2023, there were 1.6 million inadmissible aliens awaiting travel authorizations through the CHNV program” and DHS was using 50 airports worldwide to fly them in, The Center Square reported . None flown into the country have a legal basis to enter the U.S. before being paroled through the CHNV program, DHS documents the committee obtained state. "All individuals paroled into the United States are, by definition, inadmissible, including those paroled under the CHNV processes," one of the DHS documents states. The CHNV parole program was among more than a dozen that House Republicans identified as illegal and cited as reasons to impeach Mayorkas. According to the latest U.S. Customs and Border Protection data , more than 852,000 illegal foreign nationals were processed and released into the country through the CBP One App and more than 531,000 Cubans, Haitians, Nicaraguans, and Venezuelans deemed inadmissible were released into the country through the CHNV parole program, as of October. Under the Biden administration, more than three million illegal border crossers were reported from CHNV countries, The Center Square reported . Many have been directly linked to violent crimes committed against Americans, The Center Square reported .